June 15, 2021
Business News

bioAffinity Technologies to Present Poster at World Conference on Lung Cancer 2020

SAN ANTONIO, Texas–()–bioAffinity Technologies, a privately held biotech company, announced its poster “Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity” has been accepted for presentation at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, Singapore, Worldwide Virtual Event (WCLC 2020) from Jan. 28 to 31, 2021.

bioAffinity Technologies will present results of its test validation trial for CyPath® Lung, a non-invasive test for the early detection of lung cancer, that evaluated the test’s ability to distinguish…

Click here to view the original article.

Related Posts

You might also like ...

Mannatech President and CEO Al Bala Elected to Direct Selling Association Board of Directors
New Slack Research Shows How Companies Can Win the War for Talent in the Post-Pandemic World
Biological Dynamics to Participate in the Nephron Research Liquid Biopsy Innovation Symposium